HR-HPV DNA、LPT检测对宫颈鳞状细胞癌患者的诊断价值

doi:10.3969/j.issn.1671-7171.2024.03.017

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1187 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the diagnostic value of high-risk human papillomavirus(HR-HPV) deoxyribonucleic acid(DNA) combined with liquid based thin-prep cytology(LPT) in cervical squamous cell carcinoma. 【Methods】A total of 84 patients with cervical squamous cell carcinoma(cervical squamous cell carcinoma group) and 60 patients with chronic cervicitis(chronic cervicitis group) who were diagnosed and treated in Xi'an High-tech Hospital from May 2019 to April 2021 were selected, and 50 healthy women who underwent physical examination in the Xi'an High-tech Hospital during the same period were selected as the control group. The positive rates of HR-HPV DNA and LPT were compared among the three groups; The positive rates of HR-HPV DNA and LPT in patients with cervical squamous cell carcinoma at different stages and different degrees of differentiation were compared. Taking the pathological examination results as the gold standard, the diagnostic efficacy of HR-HPV DNA combined with LPT detection for cervical squamous cell carcinoma was analyzed. 【Results】The positive rates of HR-HPV DNA and LPT in the cervical squamous cell carcinoma group and the chronic cervicitis group were higher than those in the control group(P<0.05); The positive rates of HR-HPV DNA and LPT in cervical squamous cell carcinoma group were higher than those in the chronic cervicitis group. There was no significant difference in the positive rates of HR-HPV DNA and LPT in patients with cervical squamous cell carcinoma at different stages(P>0.05); There was no significant difference in the positive rates of HR-HPV DNA and LPT in patients with cervical squamous cell carcinoma of different differentiation degrees(P>0.05). Receiver operating characteristic(ROC) curve analysis showed that the sensitivity of HR-HPV DNA combined with LPT in the diagnosis of cervical squamous cell carcinoma was significantly higher than that of HR-HPV DNA and LPT alone; The AUC of HR-HPV DNA combined with LPT in the diagnosis of cervical squamous cell carcinoma was higher than that of HR-HPV DNA and LPT alone(Z=3.940,P<0.001; Z=3.968, P<0.001). 【Conclusion】 HR-HPV DNA combined with LPT is highly effective in the diagnosis of cervical squamous cell carcinoma, and can be used as an important reference index for clinical diagnosis of cervical squamous cell carcinoma.

Key words： Uterine Cervical Neoplasms/DI Neoplasms, Squamous Cell Papillomaviridae

Received: 16 February 2023

PACS:

R737.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUI Min
	CUI Jing

Cite this article:

HUI Min,CUI Jing. Diagnostic Value of HR-HPV DNA and LPT Detection in Patients with Cervical Squamous Cell Carcinoma[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 382-385.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.03.017 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I3/382

[1] 王艳艳,钟荣.血清miR21、miR155-5P及miR20a联合检测在宫颈癌早期诊断中的应用价值[J].医学临床研究,2023,40(8):1164-1167.
[2] OKUNADE K S. Human papillomavirus and cervical cancer[J].J Obstet Gynaecol,2020,40(5):602-608.
[3] LEWIS J J. Human papillomavirus testing in head and neck squamous cell carcinoma in 2020: Where are we now and where are we going?[J].Head Neck Pathol,2020,14(2):321.
[4] 杨飞翔, 江俊青, 罗克锴, 等. 鳞状上皮细胞癌抗原联合人乳头瘤病毒DNA检测对非典型鳞状上皮细胞的诊断意义[J].安徽医药, 2019, 23(7):1346-1349.
[5] 阎臻, 李新敏, 崔珺. 液基薄层细胞学联合高危型HPV检测在宫颈癌前病变筛查中的应用[J].黑龙江中医药, 2020, 49(1):305-306.
[6] PRAT J. FIGO staging for uterine sarcomas[J].Int J Gynaecol Obstet,2009,104(3):177-178.
[7] 陈必良, 魏莉. 妇产科疾病[M]. 西安:第四军医大学出版社, 2015:27-28.
[8] 王临虹, 赵更力. 宫颈病变及宫颈癌检查教程[M]. 北京:北京大学医学出版社, 2011:45-46.
[9] WILBUR D C, NAYAR R. Bethesda 2014: improving on a paradigm shift[J].Cytopathology,2015,26(6):339-342.
[10] PATEL J J, LEVY D A, NGUYEN S A, et al. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-systematic review and meta-analysis[J].Head Neck,2020,42(4):774-786.
[11] 刘妮,王丽娟.MTA2、FGFRL1在宫颈鳞状细胞癌组织中的表达及其临床意义[J].医学临床研究,2023,40(4):523-526.
[12] 王元元, 李娜. HPV-DNA联合SCC-Ag、CEA、HE4检测对宫颈癌患者的诊断价值研究[J].实用癌症杂志, 2019, 34(11):1752-1755.
[13] 汪晓菁. 液基细胞学检查联合人乳头瘤病毒检测诊断宫颈癌前病变的临床价值[J].中国妇幼保健, 2017, 32(21):5443-5445.
[14] RANTSHABENG P, KASVOSVE I, NDLOVU A, et al. Prevalence of high-risk human papilloma virus in women with high-grade squamous cell intraepithelial lesions in Botswana using Abbott Real Time HPV assay[J].PLoS One,2019,14(1):260-263.
[15] 李越峰. 肿瘤标志物联合HPV DNA与TCT检测对癌前病变及宫颈癌临床价值[J].医药论坛杂志, 2019, 40(8):27-29.
[16] 杨花, 刘辉. 高危型HPV与LPT检测对宫颈癌前病变的筛查效果[J].贵州医药, 2020, 44(3):435-436.